Therefore, UCHL1 may serve as new oncogenic target for the treatment of ER−, TNBC and ER+ breast cancer that is resistant to endocrine therapy, or potentially as an adjuvant target to supress recurrence. The gene discussed is UCHL1; the disease is breast cancer.